NYKD Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.…
Industry Peers
BiotechnologyKey Statistics
About Nykode Therapeutics (OSL: NYKD)
›
Nykode Therapeutics (OSL: NYKD) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 59 employees.
The shares were at 2.735 NOK on 19 November 2026, up 22.2% over 52 weeks. Its 52-week range is 2.058 NOK to 5.170 NOK: the price is 47.1% below the high and 32.9% above the low.
Its market capitalisation is 1.07B NOK.
Nykode Therapeutics reports return on equity of -13.4% and revenue down 46.5% year over year.
It holds more cash than debt, a net cash position of 43.01M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 7.500 NOK is 174.2% above the current price. The next earnings report is expected on 25 November 2026.